Skip to main content
. 2025 Aug 23;25:655. doi: 10.1186/s12877-025-06280-2

Table 1.

Characteristics of the study sample stratified by multidimensional frailty degree and syncope history

VARIABLE (%) Light Frailty
(n. 92, 16.4%)
Moderate Frailty
(n. 250, 44.6%)
Severe Frailty
(n. 218, 38.9%)
NO Syncope
(n. 82)
Syncope
(n. 10)
p NO Syncope
(n. 216)
Syncope
(n. 34)
p NO Syncope
(n.155)
Syncope
(n.63)
p
Age (years ± SD) 75.1 ± 6.1 75.4 ± 3.1 0.873 77.2 ± 6.7 75.7 ± 6.0 0.189 79.3 ± 7.1 80.2 ± 7.1 0.383
Sex (% female) 31.7 40.0 0.597 53.2 61.8 0.354 62.6 66.7 0.569
BMI (μ ± SD) 26.8 ± 5.6 31.0 ± 8.2 0.035 28.1 ± 5.9 28.2 ± 3.9 0.953 27.0 ± 5.8 28.5 ± 4.3 0.080
SBP (mmHg) (μ ± SD) 135.8 ± 21.5 129.9 ± 14.5 0.401 140.3 ± 21.7 134.6 ± 17.9 0.144 139.2 ± 22.1 143.1 ± 22.1 0.236
DBP (mmHg) (μ ± SD) 77.3 ± 9.3 77.2 ± 10.0 0.970 78.7 ± 11.2 78.4 ± 11.7 0.876 79.4 ± 10.5 80.6 ± 11.8 0.443
HR (bpm) (μ ± SD) 70.5 ± 10.8 62.6 ± 9.4 0.031 72.0 ± 12.1 73.2 ± 10.1 0.557 71.9 ± 10.8 73.5 ± 10.6 0.426
OH (%) 14.6 40.0 0.046 17.6 41.2 0.002 22.6 41.3 0.005
CIRS (μ ± SD) 1.7 ± 0.4 1.6 ± 0.4 0.742 1.9 ± 0.5 2.0 ± 0.4 0.286 2.0 ± 0.6 2.0 ± 0.5 0.398
Drugs n. (μ ± SD) 4.7 ± 3.3 4.4 ± 4.2 0.821 6.2 ± 3.3 6.9 ± 3.6 0.255 6.6 ± 2.9 7.4 ± 3.3 0.098
BADL lost (μ ± SD) 0.6 ± 1.0 0.6 ± 0.7 0.881 1.8 ± 1.7 2.0 ± 1.6 0.596 3.2 ± 1.6 4.3 ± 1.0 0.001
IADL lost (μ ± SD) 1.6 ± 2.1 1.4 ± 1.8 0.728 3.9 ± 2.6 4.7 ± 2.2 0.008 6.1 ± 2.1 7.0 ± 1.6 0.002
MMSE (μ ± SD) 26.2 ± 3.4 27.2 ± 0.8 0.361 22.0 ± 5.7 23.7 ± 4.2 0.182 17.3 ± 5.7 15.8 ± 7.3 0.116
GDS (μ ± SD) 3.9 ± 3.1 4.5 ± 3.9 0.632 8.0 ± 3.7 7.8 ± 2.7 0.519 9.8 ± 3.6 11.4 ± 3.0 0.002
MNA (μ ± SD) 25.9 ± 2.7 27.3 ± 2.0 0.133 21.9 ± 3.8 22.4 ± 2.9 0.423 19.1 ± 3.5 17.3 ± 3.5 0.001
Tinetti scale (μ ± SD) 25.1 ± 4.0 25.7 ± 2.7 0.599 18.0 ± 7.5 17.7 ± 7.6 0.765 13.2 ± 6.7 9.3 ± 5.3 0.001
SPPB (μ ± SD) 9.9 ± 1.9 10.7 ± 0.9 0.193 7.4 ± 2.9 7.4 ± 3.0 0.946 5.6 ± 2.8 3.4 ± 2.5 0.001
SSS (μ ± SD) 6.2 ± 3.4 7.0 ± 3.2 0.532 8.6 ± 2.7 8.7 ± 2.6 0.820 9.3 ± 2.3 10.1 ± 2.4 0.020
fr-AGILE (μ ± SD) 2.4 ± 0.8 2.3 ± 0.9 0.799 5.1 ± 0.8 5.2 ± 0.7 0.694 7.5 ± 0.7 8.0 ± 0.9 0.001
Hypertension (%) 64.6 70.0 0.737 78.7 79.4 0.925 85.2 77.8 0.188
Heart Failure (%) 24.4 40.0 0.289 34.3 47.1 0.148 33.5 41.3 0.287
CAD (%) 20.7 50.0 0.041 29.2 35.3 0.469 16.8 30.2 0.027
Aortic Stenosis (%) 1.2 10.0 0.072 2.8 5.9 0.339 3.2 7.9 0.132
Diabetes (%) 18.3 10.0 0.514 25.5 32.4 0.397 27.7 36.5 0.202
Parkinson's Disease 1.2 10.0 0.072 2.3 8.8 0.045 1.9 12.7 0.001
RAASi (%) 48.8 30.0 0.261 58.3 67.6 0.304 54.2 58.7 0.541
β-blockers (%) 19.5 20.0 0.971 31.0 44.1 0.130 27.1 36.5 0.169
α-blockers (%) 20.7 20.0 0.957 15.7 35.3 0.006 11.6 28.6 0.002
CCB (%) 26.8 30.0 0.831 31.9 35.3 0.698 36.1 38.1 0.785
Nitrates (%) 6.1 20.0 0.117 2.8 17.6 0.001 3.2 15.9 0.001
Diuretics (%) 15.9 40.0 0.063 26.4 52.9 0.002 44.5 57.1 0.091
AChEIs (%) 6.1 0.0 0.422 10.2 8.8 0.806 25.8 25.4 0.950
Memantine (%) 0.0 0.0 5.6 0.00 0.159 10.3 15.9 0.252
Antidepressant (%) 6.1 0.0 0.422 21.8 23.5 0.817 20.6 25.4 0.443
Antipsychotics (%) 4.9 10.0 0.500 14.8 5.9 0.158 28.4 31.7 0.622

Bold emphasis inside table indicate the statistical significance

Legend: SD standard deviation, μ mean, BMI Body Mass Index, SBP Systolic Blood Pressure, DBP Diastolic Blood Pressure, HR Heart Rate, OH Orthostatic Hypotension, CIRS Cumulative Illness Rating Scale, BADL Basic Activity of Daily Living, IADL Instrumental Activity Daily Living, MMSE Mini Mental State Examination, GDS Geriatric Depression Scale, MNA Mini Nutritional Assessment, SPPB Short Physical Performance Battery, SSS Social Support Scale, CAD Coronary Artery Disease, RAASi Renin–Angiotensin–Aldosterone System inhibitors, CCB Calcium Channel Blockers, AChEIs Acetylcholinesterase Inhibitors